See the DrugPatentWatch profile for azacitidine

Azacitidine, a medication used primarily for the treatment of myelodysplastic syndrome, may have an impact on graft-versus-host disease (GVHD) severity. However, the available information on this topic is limited.

A study published in the journal "Biology of Blood and Marrow Transplantation" in 2015 investigated the effect of azacitidine on GVHD in mice. The study found that azacitidine treatment reduced the severity of GVHD in mice, suggesting a potential therapeutic role for azacitidine in managing GVHD in humans [1].

Another study published in the "Journal of Clinical Oncology" in 2018 examined the use of azacitidine in patients with acute myeloid leukemia who had undergone allogeneic hematopoietic cell transplantation. The study found that azacitidine treatment was associated with a lower incidence of severe chronic GVHD, further supporting the potential of azacitidine in managing GVHD [2].

It is important to note that while these studies suggest a potential role for azacitidine in managing GVHD, more research is needed to fully understand the mechanism by which azacitidine affects GVHD severity and to establish the safety and efficacy of azacitidine in this context.

In summary, the available information suggests that azacitidine may have a beneficial effect on GVHD severity, but more research is needed to confirm these findings and to establish the safety and efficacy of azacitidine in managing GVHD.

Sources:
[1] <https://www.ncbi.nlm.nih.gov/pubmed/26251123>
[2] <https://ascopubs.org/doi/abs/10.1200/JCO.2017.76.8671>